Research Information Only. Educational content, not medical advice and not a treatment recommendation. None of the compounds on this page is FDA-approved for adult wellness use. Consult a licensed physician before considering any peptide therapy.
⚡ Head-to-Head · GH Axis Hub

CJC-1295 vs. Ipamorelin vs. Sermorelin

The most-searched three-way comparison in the GH secretagogue space is mostly a false matchup. CJC-1295 and sermorelin are both GHRH analogs competing for the same pituitary receptor; ipamorelin is a ghrelin-mimetic GHRP acting on an entirely different one. In clinical practice the real question is rarely "which of the three" — it is which GHRH analog, whether to add the GHRP, and what the evidence honestly supports.

CJC-1295 · GHRH Analog Ipamorelin · GHRP / Ghrelin Mimetic Sermorelin · GHRH Analog

Authored by Dr. Scott DelBoccio, DMD · PeptideReport.ai · September 2026

At a Glance

Three Compounds, Side by Side

The table below compares the three compounds on the dimensions that actually separate them: receptor class, pharmacokinetics, selectivity, regulatory standing, and the depth of their human evidence. Deliberately absent is a "typical dose" row — none of these compounds has an FDA-approved adult dosing protocol, and any dosing decision belongs to a prescribing physician working from baseline labs.

Dimension CJC-1295with / without DAC Ipamorelinselective GHRP SermorelinGHRH(1-29)
Class GHRH analog — engineered, degradation-resistant GHRP / ghrelin mimetic — synthetic pentapeptide GHRH analog — first 29 amino acids of native GHRH
Receptor GHRHR on pituitary somatotrophs (Gαs → cAMP → PKA) GHS-R1a, the ghrelin receptor (Gαq → IP₃ → Ca²⁺) GHRHR on pituitary somatotrophs (Gαs → cAMP → PKA)
Half-life ~6–8 days with DAC (albumin-bound depot); ~30 minutes without DAC (Mod-GRF 1-29) — two effectively different drugs ~2 hours — the longest-acting of the injectable short-course secretagogues here ~10–20 minutes — rapidly cleaved by DPP-IV and neprilysin
Selectivity GHRHR-specific by class; no meaningful ACTH/prolactin signal Defining feature: robust GH release with minimal cortisol, ACTH, and prolactin co-stimulation (Raun 1998) — unlike GHRP-6/GHRP-2 GHRHR-specific by class; no meaningful ACTH/prolactin signal
Regulatory status Never FDA-approved. ConjuChem halted development after Phase I/II. Compounding pharmacy + physician prescription only Never FDA-approved. Novo Nordisk shelved it; a later Phase II program failed on efficacy. Compounding pharmacy + physician prescription only Formerly FDA-approved (Geref, 1997, pediatric GHD); withdrawn 2008 for commercial reasons. Now compounding pharmacy + physician prescription only
Evidence level IIb — with DAC V — Mod-GRF (no DAC)
Phase I/II human pharmacodynamic data (Teichman 2006)		 IIb–IV
Preclinical selectivity data plus class-level human RCTs of other GHS-R1a agonists		 IIb — adult use Ib — pediatric GHD
Adult use extrapolates from the FDA-approval dataset
Key human data Teichman 2006 (JCEM): n=65 healthy adults; IGF-1 raised 1.5–3× baseline for 9–11 days after a single administration; GH AUC up 2–10×, pulsatility preserved Raun 1998 (selectivity + early human PK); Phase II postoperative-ileus RCT (well tolerated, efficacy endpoints not met); MK-0677 class RCTs (Nass 2008) for the receptor class Geref NDA package: multicenter pediatric RCTs, safety database of 500+ patients; growth velocity comparable to exogenous GH in pediatric GHD
Feedback-loop preservation Preserved — but DAC's continuous stimulation flattens the pulse architecture the axis normally runs on Preserved — IGF-1 negative feedback intact; GH released in amplified pulses Preserved — the closest of the three to native GHRH physiology; brief pulses, intact somatostatin control
WADA status Prohibited (S2, GH releasing factors) Prohibited (S2, GH releasing factors) Prohibited (S2, GH releasing factors)

Evidence levels follow the PeptideReport.ai system: I = FDA-approved or Cochrane-level evidence · Ib = single Western RCT · IIb = Phase I/II human data · V = preclinical only. Half-life and trial figures are drawn from the individual compound profiles and their primary citations.

Mechanism

Two Classes, Not Three Competitors

Pituitary somatotroph cells carry two independent stimulatory receptors, and these three peptides split cleanly across them. That single fact reorganizes the whole comparison: CJC-1295 and sermorelin are alternatives to each other, while ipamorelin is a complement to either.

Class 1 · GHRH Analogs
Amplitude Amplifiers
Sermorelin · CJC-1295 (both forms)
Bind the GHRH receptor and drive the Gαs → cAMP → PKA cascade, increasing both GH synthesis and vesicle release.
Amplify the GH pulses the hypothalamus already schedules — they raise pulse amplitude rather than creating new pulses.
Remain subject to somatostatin, the hypothalamic inhibitory tone; a GHRH signal arriving against high somatostatin produces a blunted response.
Within the class, the choice is pharmacokinetic: sermorelin's minutes-long action mimics native GHRH; CJC-1295 with DAC trades pulse fidelity for days of sustained stimulation.
Class 2 · GHRPs / Ghrelin Mimetics
Pulse Initiators
Ipamorelin (also GHRP-2, GHRP-6, MK-677)
Bind GHS-R1a — the receptor for ghrelin, the stomach-derived hormone — and drive the parallel Gαq → IP₃ → Ca²⁺ cascade.
Can initiate GH release directly and, critically, suppress somatostatin tone — releasing the brake as well as pressing the accelerator.
Earlier GHRPs (GHRP-6, GHRP-2, hexarelin) co-stimulate cortisol, ACTH, and prolactin; ipamorelin's structure makes it the selective member of the class.
Because the pathway is orthogonal to GHRHR signaling, a GHRP adds to a GHRH analog rather than competing with it.
Why the Cross-Class Pairing Exists

The classic pairing — a GHRH analog plus ipamorelin — is not marketing convention; it is receptor pharmacology. The two signals arrive at the same somatotroph through independent second-messenger systems (cAMP/PKA and IP₃/Ca²⁺) and converge on the same GH secretory machinery, while the GHRP arm simultaneously lowers somatostatin inhibition. In vitro and in vivo secretagogue studies show the combined GH response is additive to synergistic — greater than the arithmetic sum of either signal alone.

Two honest caveats belong next to that mechanism. First, the specific CJC-1295 + ipamorelin combination has never been evaluated in a published human randomized controlled trial; the synergy claim rests on class pharmacology, not a trial of the pairing itself. Second, because both arms still work through the pituitary, IGF-1 negative feedback remains intact for the combination — a meaningful safety property, but not a license to skip physician-ordered IGF-1 monitoring, since combined stimulation produces larger IGF-1 elevations than either agent alone.

Evidence Review

What the Human Data Actually Shows

Each compound is routinely oversold somewhere on the internet. Read against the primary literature, each has a narrower — and more interesting — evidence base than its marketing suggests.

CJC-1295
Level IIb (with DAC) · Level V (Mod-GRF)

Start with the disambiguation, because everything else depends on it. "CJC-1295 with DAC" carries a Drug Affinity Complex — a maleimide linker that covalently binds serum albumin after administration, converting the peptide into a slow-release depot with a half-life of roughly 6–8 days. "CJC-1295 without DAC" is a different molecule, properly called Modified GRF (1-29): no linker, a half-life around 30 minutes, and pharmacology much closer to sermorelin. Only the DAC form has published human trial data; Mod-GRF sits at Level V, preclinical only. A patient and physician discussing "CJC-1295" may be discussing either one.

The trial: Teichman et al. 2006 (JCEM) — a Phase I/II dose-ranging study in 65 healthy adults using single and repeat administrations of CJC-1295 with DAC at 30–120 mcg/kg (clinical-trial doses, not clinical practice figures). A single administration raised IGF-1 to 1.5–3× baseline for 9–11 days and increased GH area-under-curve 2–10× dose-dependently, with the pulsatile GH secretion pattern preserved. Adverse effects were mild — injection-site reactions, transient facial flushing, occasional headache — with no serious adverse events reported.

The honest ceiling: those endpoints are surrogate markers. No published trial has connected CJC-1295's IGF-1 elevation to functional outcomes — muscle mass, fat loss, recovery, anything a patient actually wants. ConjuChem discontinued development before Phase III, so the compound is frozen at pharmacodynamic proof-of-concept. Low-titer anti-CJC-1295 antibodies appeared in a subset of trial subjects, of unclear significance for long-term repeated use. And the DAC technology cuts both ways: continuous multi-day receptor stimulation is precisely what the pulsatility-first school of GH-axis thinking argues against.

Ipamorelin
Level IIb–IV (class-supported)

Ipamorelin's foundational paper is about what it does not do. Raun et al. 1998 characterized a pentapeptide that released GH as robustly as GHRP-6 while producing minimal ACTH, cortisol, and prolactin co-stimulation — the off-target burden that limits earlier GHRPs. That selectivity, conferred by its unusual structure (Aib and D-amino acid substitutions), is the entire clinical case for preferring ipamorelin within its class. Johansen 1999 added preclinical support, showing pulsatile GH release and improved bone mineral density in a rat osteopenia model.

The Phase II history: after Novo Nordisk shelved the compound without completing a registration program, an intravenous formulation of ipamorelin was later advanced into a Phase II randomized, placebo-controlled trial for postoperative ileus — delayed gastrointestinal recovery after bowel surgery, a plausible target for a ghrelin mimetic given ghrelin's prokinetic gut effects. Ipamorelin was well tolerated but did not meet its efficacy endpoints, and the program was not continued. That failed trial is, paradoxically, among the best controlled human tolerability data ipamorelin has.

The honest ceiling: no long-duration human efficacy trial of ipamorelin has ever been completed for any indication. Much of what is claimed about chronic GHS-R1a agonism in adults is borrowed from trials of MK-0677 (ibutamoren), a different oral agonist of the same receptor — including the Nass 2008 two-year RCT, which showed a roughly 40% IGF-1 rise and increased lean mass, but also an insulin-resistance signal that is the reason glucose monitoring is non-negotiable for this class. Extrapolating MK-0677 results to ipamorelin assumes a class equivalence that has never been formally tested.

Sermorelin
Level IIb adult use · Ib pediatric GHD

Sermorelin is the only one of the three that has ever held an FDA approval. Geref (Serono) was approved in 1997 for pediatric growth hormone deficiency, on multicenter randomized trials showing growth-velocity improvement comparable to exogenous GH, with a safety database of more than 500 patients whose adverse events were chiefly injection-site reactions and headache. Serono discontinued Geref in 2008 for commercial reasons — not a safety recall and not an efficacy failure — which is why the human PK, PD, and tolerability data remain citable today.

The regulatory fact: the historical Geref label dose was 0.03 mg/kg/day subcutaneously — a pediatric GHD prescribing figure cited here strictly as regulatory history, not as any form of adult dosing guidance. No adult wellness dose has ever been FDA-reviewed.

The honest ceiling: the approval was pediatric. Adult longevity use extrapolates from that dataset plus rationale papers (Walker 2006) and class-level secretagogue reviews (Sigalos & Pastuszak 2018) — a legitimate mechanistic extrapolation, but Level IIb, not Level I. Sermorelin's 10–20 minute half-life is simultaneously its physiological virtue (a brief, native-pattern pulse, fully subject to somatostatin and IGF-1 feedback) and its practical limitation: it produces the smallest and shortest GH signal of the three, and its response depends on intact pituitary somatotroph reserve, which declines with age.

Clinical Reasoning

How a Physician Chooses

In practice the decision is goal-driven, not brand-driven. These are the mappings a prescribing physician actually reasons through — every one of them ending in individualized titration against labs, not a fixed protocol.

If the priority is
Staying closest to native physiology
Sermorelin is the conservative anchor: a GHRH(1-29) fragment with a minutes-long action, fully pulsatile output, intact somatostatin and IGF-1 feedback, and the deepest human safety file of the three. Physicians who prioritize pulse architecture reach for it — or for Mod-GRF, accepting that the latter's evidence is preclinical.
If the priority is
The strongest published adult IGF-1 data
CJC-1295 with DAC holds the best adult pharmacodynamic dataset (Teichman 2006) and the largest, most durable IGF-1 elevation. The trade is physiological: multi-day continuous GHRHR stimulation flattens pulse architecture, and the surrogate-endpoint ceiling means no one has shown the IGF-1 rise buys a functional outcome.
If the priority is
Adding GH drive without HPA or prolactin cost
Ipamorelin is the only GHRP whose selectivity profile supports chronic use logic: GH amplification with minimal cortisol, ACTH, or prolactin co-stimulation. It is rarely chosen as monotherapy; its usual role is the second receptor in a GHRH + GHRP pairing.
If the priority is
Maximum GH output per unit of stimulation
The cross-class pairing — a GHRH analog plus ipamorelin — exploits dual-receptor convergence and somatostatin suppression, typically letting a physician run each arm lower than either would need alone. The combination itself is untested in a published RCT, and combined IGF-1 elevation demands closer lab surveillance, not less.
Why IGF-1 is the steering instrument: GH itself pulses minute-to-minute and is nearly useless as a single blood draw, but IGF-1 integrates the axis's whole 24-hour output into one stable, measurable number. That makes it the titration anchor for every compound on this page: a physician documents an age- and sex-adjusted baseline, rechecks after initiation, and steers toward an age-appropriate normal range — restoration, not maximization. Values pushing the upper quartile of age-normal argue for dose reduction or pause, because sustained supraphysiological IGF-1 is exactly the exposure the epidemiological cancer-association literature worries about. Fasting glucose and HbA1c ride along on the same schedule, since GH is counter-regulatory to insulin. All of this is physician-ordered lab work — it is the mechanism by which secretagogue use stays inside physiological bounds, and it has no self-directed substitute.
Safety

Safety Comparison

Most of the safety story is shared, because all three ultimately raise GH and IGF-1. The differentiators sit at the margins: receptor selectivity, exposure duration, and how much human data stands behind each tolerability claim.

Consideration CJC-1295 Ipamorelin Sermorelin
Documented human tolerability Teichman 2006: no serious adverse events in n=65; injection-site reactions, transient flushing, headache Early human PK plus the postoperative-ileus Phase II: well tolerated; no long-duration adult dataset Geref FDA trials, 500+ patients: injection-site reactions and headache predominate; rare hypersensitivity reported
GH class effects (fluid retention, joint stiffness, carpal tunnel) Dose-dependent risk; most plausible of the three given multi-day sustained GH elevation Class risk present; amplified in combination regimens where total GH output is higher Lowest theoretical exposure — briefest GH signal — but the class effects remain possible
Glucose / insulin sensitivity Modest transient fasting-glucose rise noted in the Phase I/II trial; GH is counter-regulatory to insulin Receptor-class warning: insulin resistance emerged in the Nass 2008 MK-0677 RCT — the reason glucose monitoring is mandatory for GHS-R1a agonists Same class physiology; caution flagged in pre-diabetic and diabetic patients in the profile literature
Hormonal off-target effects None characteristic beyond the GH axis The selectivity advantage: minimal cortisol, ACTH, prolactin — the specific liability of GHRP-6/GHRP-2 that ipamorelin was designed away from None characteristic beyond the GH axis
Compound-specific flags Low-titer anti-drug antibodies in trial subjects (significance unknown); blunted pulsatility from continuous DAC exposure Evidence borrowed from MK-0677 assumes untested class equivalence; appetite stimulation possible via ghrelin mimicry Response depends on pituitary somatotroph reserve — may underperform in older patients; rare hypersensitivity
IGF-1 / neoplasia consideration Shared across all three: epidemiological cohorts associate high-normal-and-above IGF-1 with certain cancers. Causality in the secretagogue setting is unproven, but it is the reason physician-ordered IGF-1 titration targets age-appropriate — not maximal — ranges, and the reason active malignancy is treated as a contraindication throughout the secretagogue literature.
The Data That Does Not Exist
None of the three has long-term safety data for healthy-adult wellness use. No multi-year randomized trial has followed healthy adults on CJC-1295, ipamorelin, or sermorelin for the purposes they are most commonly prescribed for today. Every long-horizon safety statement about these compounds is an extrapolation — from short trials, from pediatric data, from a different molecule at the same receptor, or from GH physiology itself. A candid physician says so before writing anything.
Sourcing and Athletes
All three compounds are legitimately available in the US only through licensed compounding pharmacies, with a physician prescription and lab monitoring. "Research chemical" websites selling these peptides for human use operate outside pharmacy regulation, with no purity, sterility, or identity assurance — they are not a legitimate source. Separately, all three are WADA-prohibited (class S2, growth hormone releasing factors); competitive athletes subject to anti-doping testing face multi-year bans for detected use.
Common Questions

Frequently Asked Questions

What is the difference between CJC-1295 and sermorelin?

Both are GHRH analogs acting on the same pituitary GHRH receptor, so they are variations on one mechanism rather than two different mechanisms. Sermorelin is the first 29 amino acids of native GHRH, has a half-life of roughly 10-20 minutes, and carries a former FDA approval (Geref, approved in 1997 for pediatric growth hormone deficiency and discontinued in 2008 for commercial reasons). CJC-1295 is an engineered GHRH analog built to resist enzymatic degradation; with the DAC albumin-binding linker its half-life extends to roughly 6-8 days, producing sustained GH-axis stimulation rather than the brief pulse sermorelin triggers. Sermorelin has the deeper human safety record; CJC-1295 with DAC has the stronger published adult pharmacodynamic data (Teichman 2006).

Why are CJC-1295 and ipamorelin used together?

Because they act on two different receptors on the same pituitary somatotroph cells. CJC-1295 is a GHRH analog signaling through the GHRH receptor and its cAMP/PKA pathway, while ipamorelin is a ghrelin mimetic signaling through GHS-R1a and its IP3/calcium pathway. The two signals converge on the same GH secretory machinery, and GHS-R1a activation additionally suppresses somatostatin, the hypothalamic brake on GH release. The secretagogue pharmacology literature supports dual-receptor stimulation as additive to synergistic, producing greater GH output than either compound alone. The receptor-level rationale is well established, but the specific CJC-1295 plus ipamorelin combination has not been evaluated in a published human randomized controlled trial.

Is sermorelin FDA-approved?

Not currently. Sermorelin was FDA-approved in 1997 as Geref (Serono) for pediatric growth hormone deficiency, and the manufacturer discontinued it in 2008 for commercial reasons, not because of any safety or efficacy problem. That historical approval means sermorelin has genuine controlled human trial data behind it, which is rare among GH-axis peptides. Today sermorelin, like CJC-1295 and ipamorelin, is available in the United States only through compounding pharmacies with a physician prescription, and none of the three is FDA-approved for adult wellness or anti-aging use.

Which is safest: CJC-1295, ipamorelin, or sermorelin?

No head-to-head human safety trial exists, and none of the three has long-term safety data in healthy adults using them for wellness purposes; that absence applies equally to all three. Within that limit, each has a distinct safety argument. Sermorelin has the deepest human safety record because FDA approval required controlled trials. Ipamorelin has the cleanest receptor selectivity, stimulating GH with minimal cortisol, ACTH, or prolactin co-release. CJC-1295 has documented Phase I/II tolerability but produces days-long GH-axis stimulation that departs furthest from normal pulsatile physiology. All three share GH class considerations, including fluid retention, joint symptoms, reduced insulin sensitivity, and theoretical concerns about sustained IGF-1 elevation, which is why physician-ordered IGF-1 and metabolic monitoring matters regardless of the agent.

What is the difference between CJC-1295 with DAC and without DAC?

They are effectively two different compounds sharing a name. CJC-1295 with DAC carries a Drug Affinity Complex linker that covalently binds serum albumin after administration, extending its half-life to roughly 6-8 days; it is the version studied in the Teichman 2006 Phase I/II trial and holds Level IIb evidence. CJC-1295 without DAC, more accurately called Modified GRF (1-29) or Mod-GRF, lacks the linker, has a half-life of roughly 30 minutes, behaves much more like sermorelin pharmacologically, and has only preclinical Level V evidence. Any clinical conversation about CJC-1295 should begin by clarifying which compound is meant.

Can competitive athletes use these peptides?

No. CJC-1295, ipamorelin, and sermorelin are all prohibited for competitive athletes under the World Anti-Doping Agency Prohibited List: GHRH analogs and growth hormone releasing peptides fall under class S2 as growth hormone releasing factors. Detected use carries multi-year competition bans. Any athlete subject to anti-doping testing should assume all three compounds are banned and consult their anti-doping organization before considering any GH-axis peptide.

Physician Assessment

My Read on This Comparison

Dr. DelBoccio's Clinical Perspective

When a patient asks me to compare these three, I usually start by declining the premise. Two of them do the same job at the same receptor; the third does a different job at a different receptor. Once that clicks, the conversation gets much more productive — we stop ranking three products and start talking about one axis with two inputs, and about which input, if any, the patient's labs and goals actually justify stimulating.

My honest hierarchy of confidence runs: sermorelin for human safety data, because an FDA approval — even a pediatric one, even a discontinued one — buys a depth of controlled tolerability evidence nothing else here can match; CJC-1295 with DAC for adult pharmacodynamic proof, because Teichman 2006 is the single best adult dataset in this trio; and ipamorelin for pharmacological elegance, because its selectivity is real and well-documented, even though its direct human evidence is the thinnest of the three. Notice that no compound wins all three columns. That is the comparison in miniature.

What I care most about is what none of them has: long-term outcome data in the healthy adults actually using them. Surrogate IGF-1 elevations are not lean mass, are not recovery, are not healthspan. Feedback-loop preservation is a genuinely meaningful safety property — it is the reason I take secretagogues seriously at all when I would not touch exogenous GH for wellness purposes — but preserved feedback is a seatbelt, not a guarantee. If a patient pursues any of these, it should be through a licensed physician who documents a baseline, measures IGF-1 and glucose on a schedule, titrates toward age-appropriate ranges, and is willing to stop. Anyone selling certainty in this space — in either direction — is selling something other than the evidence.

Dr. Scott DelBoccio, DMD Author & Clinical Reviewer · PeptideReport.ai